Law360, Chicago (July 27, 2012, 4:02 PM ET) -- Medifast Inc. subsidiary Jason Pharmaceuticals Inc. has agreed to pay $3.7 million under a proposed deal to resolve the U.S. Federal Trade Commission's probe of advertising claims for its weight-loss programs, the company said Thursday.
Jason Pharmaceuticals said the FTC had expressed concern that some of its claims did not meet current standards for substantiation, and voiced a particular objection to the company's use of the phrase "up to" in connection with its ads' weight loss claims.
Under the proposed consent agreement, the company agreed to...
Medifast Unit To Fork Over $4M To FTC Over Weight-Loss Ads
To view the full article, take a free trial now.
